P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016
Published Jun 30, 2016
47 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016, provides in depth analysis on P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted pipeline therapeutics.

The report provides comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
- The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic

  
Source:
Document ID
GMDHC0156TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Overview71
Therapeutics Development84
  P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Products under Development by Stage of Development81
  P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Products under Development by Therapy Area91
  P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Products under Development by Indication102
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Products under Development by Companies142
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Therapeutics Assessment166
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action171
  Assessment by Route of Administration182
  Assessment by Molecule Type202
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Companies Involved in Therapeutics Development226
  Affectis Pharmaceuticals AG221
  Axxam SpA231
  Biosceptre (Aust) Pty Ltd241
  Evotec AG251
  Johnson &Johnson261
  Medestea Research &Production S.p.A.271
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Drug Profiles2813
  AFC-5128 Drug Profile281
  BIL-010t Drug Profile291
  BIL-011t Drug Profile301
  BIL-03n Drug Profile311
  BIL-03s Drug Profile321
  BIL-04s Drug Profile331
  BIL-06v Drug Profile341
  BIL-07v Drug Profile351
  EVT-401 Drug Profile361
  JNJ-47965567 Drug Profile371
  MED-1101 Drug Profile381
  Small Molecule to Antagonize P2X7 Receptor for Central Nervous System Drug Profile391
  Small Molecules to Antagonize P2RX7 for CNS Disorders and Autoimmune Disorders Drug Profile401
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Dormant Projects411
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Discontinued Products421
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Featured News &Press Releases433
  Dec 18, 2014: Alzheimer s Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer s Disease431
  Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma431
  Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists441
  Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401441
  Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist451
Appendix462
  Methodology461
  Coverage461
  Secondary Research461
  Primary Research461
  Expert Panel Validation461
  Contact Us461
  Disclaimer471

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/P2X-Purinoceptor-7-P2Z-Receptor-or-P2RX7-Pipeline-Review-H1-2016-2088-16080>
  
APA:
Global Markets Direct - Market Research. (2016). P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/P2X-Purinoceptor-7-P2Z-Receptor-or-P2RX7-Pipeline-Review-H1-2016-2088-16080>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.